Evidence map›Paper›PMID 35872338›Full record

ArticleLeukemia research2022

Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in France.

Pierre-Yves Dumas, Sarah Bertoli, Caroline Bonmati, Martin Carre, Juliette Lambert, Mario Ojeda-Uribe, Sylvain Chantepie, Franciane Paul, Eric Jourdan, Stéphanie Haiat and 14 more

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Pierre-Yves DumasCHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, F-33000 Bordeaux, France; BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, F-33000 Bordeaux, France. Electronic address: pierre-yves.dumas@u-bordeaux.fr.
Sarah BertoliService d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Cancer Research Center of Toulouse, UMR1037 INSERM, ERL5294 CNRS, Toulouse, France.
Caroline BonmatiService d'Hématologie, CHU Nancy Brabois, 54500 Vandoeuvre les Nancy, France.
Martin CarreService d'Hématologie clinique, CHU Grenoble Alpes, 38700 La Tronche, France.
Juliette LambertService d'Hématologie, CH de Versailles, 78150 Le Chesnay, France.
Mario Ojeda-UribeGHRMSA, Hôpital E Muller, Service d'Hématologie Clinique et Unité de Thérapie Cellulaire, 68070 Mulhouse, France.
Sylvain ChantepieService d'Hématologie, CHU de Caen, 14000 Caen, France.
Franciane PaulDépartment d'Hématologie clinique, CHU de Montpellier, 34905 Montpellier, France.
Eric JourdanHématologie Clinique, Institut de Cancérologie du Gard - CHU de Nîmes, 30029 Nîmes, France.
Stéphanie HaiatService d'Hématologie, CH Sud Francilien, 91106 Corbeil Essonnes, France.
Emmanuelle TavernierInstitut de Cancérologie Lucien Neuwirth, 42270 Saint-Priest-en-Jarez, France.
Pierre PeterlinService d'Hématologie clinique, Nantes University Hospital, Nantes, France.
Jean-Pierre MarolleauService d'Hématologie clinique et Thérapie cellulaire, CHU Amiens-Picardie, Amiens, France.
Kamel LaribiDepartment of Hematology, Centre Hospitalier Le Mans, Le Mans, France.
Corentin OrvainCHU d'Angers, Maladies du Sang, Angers, France; Univ Angers, Inserm, CRCINA, F-49000 Angers, France.
Quentin CabreraCHU Réunion Sud - Site de Saint-Pierre, Saint-Pierre, France.
Pascal TurlureService d'Hématologie et Thérapie Cellulaire du CHU Dupuytren, Limoges, France.
Stéphane GiraultService d'Hématologie, CH de Brive, Brive, France.
Marie BalsatService d'Hématologie, Hospices civils de Lyon, Lyon, France.
Marc BernardService d'Hématologie clinique, CHU de Rennes, Rennes, France.
Marie-Christine BeneService d'Hématologie Biologique, Nantes, France.
Arnaud PigneuxCHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, F-33000 Bordeaux, France; BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, F-33000 Bordeaux, France.
Hervé DombretHôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France; Institut de Recherche Saint-Louis, Université de Paris, Paris, France.
Christian RécherService d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Cancer Research Center of Toulouse, UMR1037 INSERM, ERL5294 CNRS, Toulouse, France. Electronic address: recher.christian@iuct-oncopole.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Leukemia, Myeloid, AcuteAcute DiseaseAdultFranceHumansSARS-CoV-2Acute lymphoid leukemiaAcute myeloid leukemiaSARS-CoV-2

Identifiers

PMID35872338
PMCPMC9212547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.